Company: NIVFW
Filing Date: 2025-04-22
Form Type: 20-F
Source: 0001213900-25-033966
Chunk: 55

Company: NewGenIvf Group Ltd
Filing Date: 2025-04-22
Form: 20-F
Item: Item 4
Chunk 55
---
 tourists seeking high quality, cost effective and comprehensive fertility solutions. According
to China Insights Industry Consultancy Limited (“ CIC”), the demand for fertility tourism is driven by a variety of factors
including the prevalence of infertility, the introduction of the Three-Child policy in China, the improved understanding of assisted reproductive
technology and increased affordability of ARS. To address these needs, NewGenIvf plans to offer its customers a “hassle-free”,
seamless and integrated ARS and hospitality arrangement experience. To complement its fertility services, NewGenIvf intends to integrate
its offerings with additional services for traveling patients, most of whom are first-time fertility tourists, such as translation service,
hotel arrangement and airport pickup services. NewGenIvf plans to enhance its customers’ experience by entering into exclusive cooperation
arrangements with local premium hospitality providers.

Continue to Invest in Laboratories and Facilities

NewGenIvf believes laboratories
and treatment facilities are critical to supporting its future research, development and clients experience. NewGenIvf currently operates
two laboratories that offer IVF services, one in Thailand and one in Cambodia, and plans to continue to scale up its existing laboratories.
NewGenIvf plans to continue to invest in upgrading its laboratories and facilities to complement its growth and expansion, which it believes
will help NewGenIvf maintain an edge over its competitors with regard to technology, operational efficiency, scalability, and client experience.

NewGenIvf intends to develop
advanced facilities for its existing laboratories, which will be conducting research on ARS related basic science and experiments relating
to emerging technologies to improve ARS success rates and lower costs. NewGenIvf also plans to correlate its data on patient treatment
protocols to the embryo physiologic data and the pregnancy success rate-related data to identify better treatment protocols to increase
ARS success rates. NewGenIvf intends to continue to actively promote technological cooperation with tertiary institutions to discover
ways to improve its IVF success rates. Furthermore, NewGenIvf seeks to actively deploy the technology that it possesses to expand the
services it provides.

NewGenIvf has accumulated
experience in treating patients over 40 years old with premature ovarian failure and patients who have had recurrent ARS implementation
failure, by, for the example, injecting platelet rich plasma into the ovaries to stimulate and support growth of the follicles. NewGenIvf
is also implementing certain technological advancements relevant to the ARS industry, including microfluidics, automated sperm analysers,
time l